Immunovaccine closes $14.4 million bought deal offering with over-allotment option exercised in full

15 February 2018

On February 15, 2018, Immunovaccine Inc. (TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that it had closed its previously announced bought deal public offering of common shares, including exercise of the over-allotment option in full, raising gross proceeds of $14.375 million.

The offering was conducted by a syndicate of underwriters led by Echelon Wealth Partners Inc. and including National Bank Financial Inc. and Bloom Burton Securities Inc.

Gowling WLG advised the underwriters with a team that included Andre Poles, Josh Almario and Josh Rosen.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Capital Markets